FIELD: biotechnology.
SUBSTANCE: described is an antibody for treating cancer, comprising: (1) Fab-specific antigen-binding Fab domain; (2) CD137-binding Fab domain and (3) FcRn-binding domain, wherein the FcRn-binding domain is an Fc region of the antibody with reduced binding activity with the Fcγ-receptor. What is also described is a pharmaceutical composition containing said antibody. Invention is intended for cancer.
EFFECT: invention leads to activation of immune cells and thereby leads to anti-tumor activity with no side effects such as hepatotoxicity.
15 cl, 19 dwg, 9 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| METHOD FOR PRODUCING A POLYPEPTIDE HETEROMULTIMER | 2014 |
|
RU2758952C1 |
| METHOD OF PRODUCING A POLYPEPTIDE HETEROMULTITERS | 2014 |
|
RU2730594C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
